Kazia Annual Report 2022

20 DIRECTORS’ REPORT GENERAL INFORMATION Page Director’s Report 21 Auditor’s independent declaration 38 Statement of profit or loss and other comprehensive income 39 Statement of financial position 40 Statement of changes in equity 41 Statement of cash flows 43 Notes to the financial statements 44 Directors’ declaration 75 Independent auditor’s report to the members of Kazia Therapeutics Limited 76 Shareholder information 80 Corporate directory iii The financial statements cover Kazia Therapeutics Limited as a consolidated entity consisting of Kazia Therapeutics Limited and the entities it controlled at the end of or during the year. The financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited’s functional and presentation currency. Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: Three International Towers, Level 24 300 Barangaroo Avenue Sydney NSW 2000 A description of the nature of the consolidated entity’s operations and its principal activities are included in the Directors’ report, which is not part of the financial statements. The financial statements were authorised for issue, in accordance with a resolution of directors, on 29 August 2022. The directors have the power to amend and reissue the financial statements. CONTENTS

RkJQdWJsaXNoZXIy MjE2NDg3